| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.043 | 0.8 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.0085 | 0.8 |